Sign In
Buy ARWR
$82.00
+0.180 (+0.220%)
At Close: Jun 22, 2026
Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal
07:44am, Friday, 05'th Sep 2025
Shares in Arrowhead Pharmaceuticals (ARWR 0.72%) rose by more than 27% in the week to Friday morning. The company's bold aim is to have "20 individual products, either partnered or wholly owned, in cl
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Citi's 2025 Biopharma Back To School Conference (Transcript)
04:00pm, Wednesday, 03'rd Sep 2025
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Citi's 2025 Biopharma Back to School Conference September 3, 2025 1:00 PM EDT Company Participants Dr. Christopher Anzalone - Chairman, CEO & President C
Arrowhead: Upcoming Plozasiran PDUFA Review Date And Subsequent Expansion In Place
01:15pm, Wednesday, 03'rd Sep 2025
Arrowhead stock is a Strong Buy due to significant pipeline progress, especially the upcoming FDA PDUFA review date of plozasiran for familial chylomicronemia syndrome. The PALISADE phase 3 trial for
Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement
07:30am, Tuesday, 02'nd Sep 2025
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a global licensing and collaboration agreement with Novartis for ARO-SNCA, Arrowhead's precl
Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences
07:30am, Wednesday, 27'th Aug 2025
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: European Society of Ca
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has elected to receive approximately $50 million worth of Arrowhead common stock and
Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2025 Earnings Call Transcript
08:48pm, Friday, 08'th Aug 2025
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q3 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Andy Davis - SVP of Cardiovascular & Head of Metabolic Franchise Bruce D.
Arrowhead (ARWR) Q3 Revenue Drops 41%
05:37pm, Thursday, 07'th Aug 2025
Arrowhead (ARWR) Q3 Revenue Drops 41%
Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results
04:01pm, Thursday, 07'th Aug 2025
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 third quarter ended June 30, 2025. The Company is host
Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi
06:30am, Friday, 01'st Aug 2025
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majori
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
04:30pm, Thursday, 24'th Jul 2025
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on July 22, 2025, the Co
Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics
08:00am, Wednesday, 23'rd Jul 2025
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today issued a statement to address questions about the status of its ongoing Exclusive License and Collabor
How The Negative Developments At Sarepta Therapeutics Impact Arrowhead Pharmaceuticals
01:30pm, Tuesday, 22'nd Jul 2025
Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price due to concerns over milestone payments and clinical program continuity. Arrowhead's financial position r
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results
04:01pm, Monday, 21'st Jul 2025
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 7, 2025, at 4:30 p.m. ET to discus
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subject in the YOSEMITE Phase 3 clinical trial of zodasiran, the
